Effect of Open-label Placebo on Children and Adolescents With Functional Abdominal Pain or Irritable Bowel Syndrome
Samuel Nurko(Boston Children's Hospital), John M. Kelley(Harvard University), Steven L. Ciciora(Nationwide Children's Hospital), Sean R. Zion(Stanford University), Ted J. Kaptchuk(Beth Israel Deaconess Medical Center), Joe Kossowsky(Boston Children's Hospital), John M. Rosen(Children's Mercy Hospital), Kelsey Hawthorne(Boston Children's Hospital), Rina Wu(Shenyang Agricultural University), Karla Vaz(Nationwide Children's Hospital), Miguel Saps(University of Miami)
Cited by 58
Related Papers
Using social and behavioural science to support COVID-19 pandemic response
|Nature Human Behaviour|2020|5.1k
Biological, clinical, and ethical advances of placebo effects
|The Lancet|2010|1.3k
Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome
|BMJ|2008|1.2k
Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference
|Gastroenterology|2018|1.1k
Childhood Functional Gastrointestinal Disorders: Neonate/Toddler
|Gastroenterology|2016|1.1k